Apogee Therapeutics Inc. Common Stock APGE · Stock Open Apogee Therapeutics Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Apogee Therapeutics Inc. Common Stock Analysis (APGE)
Is Apogee Therapeutics Inc. Common Stock a good investment? Apogee Therapeutics Inc. Common Stock (APGE) is currently trading at 135.07 USD. Market analysts have a consensus price target of 134.62 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Apogee Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -5.20.
Investor FAQ
Does Apogee Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Apogee Therapeutics Inc. Common Stock?
Apogee Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -4.34.
Company Profile
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Community Discussion